Enlivex Cuts Workforce About 60% in Cost Reduction Plan
Enlivex will wind down non-clinical R&D, focus resources on its Phase 2b Allocetra knee osteoarthritis trial and reduce management salaries. The company expects topline six-month trial data by mid-2027.
Enlivex Ltd. said it is implementing an immediate cost-reduction plan to substantially lower cash burn and concentrate resources on its Phase 2b clinical trial of Allocetra™ for patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The company expects topline data for the trial’s six-month endpoint by mid-2027. The plan includes winding down all research and development activities unrelated to the Phase 2b trial, effective immediately, and dedicating resources to the trial’s execution.
The company also plans to reduce its workforce by approximately 60% and cut management and CEO salaries. The announcement was made in Nes-Ziona, Israel, on Oct. 19, 2026. As part of related activities, Enlivex is reducing its workforce by approximately 60%.
The Company will cut salaries for its management team by 20%. The Chief Executive Officer’s salary will be reduced by 40%.